Development of pharmacological agents for targeting neurotrophins and their receptors

Trends in Pharmacological Sciences

Volumn 21, Issue 3, 2000, Pages 93-98

  Saragovi, H Uri ^a   Gehring, Kalle ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; ESTROGEN; KYNURENIC ACID DERIVATIVE; NEUROTROPHIN; NEUROTROPHIN RECEPTOR; NUCLEOSIDE ANALOG; PEPTIDE; PURINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RECEPTOR BLOCKING AGENT; STAUROSPORINE DERIVATIVE; VITAMIN D DERIVATIVE;

AGONIST; CANCER; DEGENERATIVE DISEASE; DRUG DEVELOPMENT; HUMAN; NEUROPATHY; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG DESIGN; HUMANS; NERVE GROWTH FACTORS; RECEPTORS, NERVE GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0034161454     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(99)01444-3     Document Type: Review

References (41)

1. Barbacid M. The Trk family of neurotrophin receptors. J. Neurobiol. 25:1994;1386-1403.
2. NTR decide? Neuron. 18:1997;187-190.
3. Ladiwala U.et al. p75 neurotrophin receptor expression on adult human oligodendrocytes: signaling without cell death in response to NGF. J. Neurosci. 18:1998;1297-1304.
4. Maliartchouk S., Saragovi H.U. Optimal NGF trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands. J. Neurosci. 17:1997;6031-6037.
5. Saragovi H.U., Burgess K. Small molecule and protein-based neurotrophic ligands: agonists and antagonists as therapeutic agents. Expert Opin. Ther. Pat. 9:1999;737-751.
6. Bogenmann E.et al. Regulation of NGF responsiveness in human neuroblastoma. Oncogene. 17:1998;2367-2376.
7. Muragaki Y.et al. Nerve growth factor induces apoptosis in human medulloblastoma cell lines that express TrkA receptors. J. Neurosci. 17:1997;530-542.
8. LeSauteur L.et al. Small molecule nerve growth factor analogs image receptors in vivo. Nat. Biotech. 14:1996;1120-1122.
9. Hefti F. Neurotrophic factor therapy for nervous system degenerative diseases. J. Neurobiol. 25:1994;1418-1435.
10. Aebischer P.et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2:1996;696-699.
11. Haase G.et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat. Med. 3:1997;429-436.
12. Marshall J.et al. Nerve growth factor modifies the expression of inflammatory cytokines by mast cells via a prostanoid-dependent mechanism. J. Immunol. 162:1999;4271-4276.
13. McMahon S.et al. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat. Med. 1:1995;774-780.
14. Saragovi H.U.et al. A TrkA selective, fast internalizing nerve growth factor-antibody complex induces trophic but not neuritogenic signals. J. Biol. Chem. 102:1998;34933-34940.
15. Wrighton N.C.et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 273:1996;458-463.
16. Chaiken I.M., Williams W.V. Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design. Trends Biotech. 14:1996;369-375.
17. Apfel S. Neurotrophic factors in peripheral neuropathies: therapeutic implications. Brain Pathol. 9:1999;393-413.
18. Saragovi H.U.et al. Loops and secondary structure mimetics: development and applications in basic science and rational drug design. Biotechnology. 10:1992;773-778.
19. Pan W.et al. Permeability of the blood-brain barrier to neurotrophins. Brain Res. 788:1998;87-94.
20. Poduslo J.et al. Putrescine-modified nerve growth factor: bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution. J. Neurochem. 71:1998;1651-1660.
21. Wu D., Pardridge W. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc. Natl. Acad. Sci. U. S. A. 96:1999;254-259.
22. Maliartchouk S.et al. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol. Pharmacol. 57:2000;385-391.
23. LeSauteur L.et al. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. J. Biol. Chem. 270:1995;6564-6569.
24. Debeir T.et al. An NGF antagonist mimetic provokes retrieval of cortical cholinergic presynaptic boutons in the brain of the adult rat. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4067-4072.
25. Maliartchouk S.et al. Genuine monovalent ligands of trka nerve growth factor receptors reveal a novel pharmacological mechanism of action. J. Biol. Chem. 2000;. (in press).
26. Dooley C.et al. An all d-amino acid opioid peptide with central analgesic activity from a combinatorial library. Science. 266:1994;2019-2022.
27. Owolabi J.et al. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J. Pharmacol. Exp. Ther. 289:1999;1271-1276.
28. Spiegel K.et al. PD 90780, a non-peptide inhibitor of nerve growth factor's binding to the p75 NGF receptor. Biochem. Biophys. Res. Commun. 217:1995;488-494.
29. Behl C., Holsboer F. The female sex hormone oestrogen as a neuroprotectant. Trends Pharmacol. Sci. 20:1999;441-444.
30. Kaneko M.et al. Neurotrophic 3,9-bis [(alkylthio)methyl]- and -bis(alkoxymethyl)- K-252a derivatives. J. Med. Chem. 40:1997;1863-1869.
31. Pollack S.et al. The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor. Mol. Pharmacol. 56:1999;185-195.
32. Steiner J.P.et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat. Med. 3:1997;421-428.
33. Harper S.et al. Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. Neuroscience. 88:1999;257-267.
34. Aloe L.et al. The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy. 102:1997;883-894.
35. Torcia M.et al. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell. 85:1996;345-356.
36. Rosenbaum T.et al. Pancreatic beta cells synthesize and secrete nerve growth factor. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7784-7788.
37. Yaar M.et al. The trk family of receptors mediates nerve growth factor and neurotrophin-3 effects in melanocytes. J. Clin. Invest. 94:1994;1550-1562.
38. Dionne C.et al. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin. Cancer Res. 102:1998;1887-1898.
39. Missale C.et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc. Natl. Acad. Sci. U. S. A. 90:1993;7961-7965.
40. Donovan M.J.et al. Identification of the neurotrophin receptors p75 and trk in a series of Wilms' tumors. Am. J. Pathol. 145:1994;792-801.
41. Lambiase A.et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. New Engl. J. Med. 338:1998;1174-1180.